Development Policy Blog: MMV's CEO, David Reddy & TB Alliance's President and CEO, Mel Spigelman discuss how PDPs reduce industry and donor risks for investment in neglected disease research by leveraging funding and employing strict portfolio management strategies.
Product Development Partnerships (PDPs) have been active, and actively engaging Australian research expertise, for over ten years. Only now is their significant contribution to global health being fully recognized. PDPs offer a new way of meeting development aims consistent with the government’s interest in increasing engagement with the private sector to achieve better development outcomes, as well as raising productivity and private-sector-led economic development. Australian scientists have made a significant contribution from the earliest beginnings of this innovative global approach to tackling diseases such as TB and malaria.
PDPs are public-private partnerships that reduce industry and donor risks for investment in neglected disease research by leveraging funding and employing strict portfolio management strategies. Partner funding is pooled to support broad product pipelines, allowing partners, including governments and private sector players, to contribute to the R&D enterprise without having to bear the entire cost and risk themselves. Strong governance structures ensure programs are conducted efficiently, and include independent review of projects as they progress through defined transition points.
Today there are 16 major PDPs operating globally, each with a specialized focus on vaccines, microbicides, preventative treatments, therapeutic products or diagnostics. PDPs have developed a unique model with the following characteristics.....
Read the full article on the Development Policy Blog.